Prostatype Genomics AB (FRA:PGO0) EPS (Basic): €-0.10 (TTM As of Dec. 2025)


FRA:PGO0 Prostatype Genomics AB FRA:PGO0
25 GF Score
Price €0.03
GF Value €0.01
! 5 Warning Signs
View Full Analysis

What is Prostatype Genomics AB EPS (Basic)?

Prostatype Genomics AB FRA:PGO0 -5.42% 25 EPS (Basic) is €-0.10 as of Dec. 2025. GuruFocus rates FRA:PGO0 with a GF Score™ of 25/100 and a GF Value™ of €0.01. The stock has 5 warning signs investors should review.

Prostatype Genomics AB's basic earnings per share (Basic EPS) for the six months ended in Dec. 2025 was €-0.04. Its basic earnings per share (Basic EPS) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.

Prostatype Genomics AB's EPS (Diluted) for the six months ended in Dec. 2025 was €-0.04. Its EPS (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.10.

Prostatype Genomics AB's EPS without NRI for the six months ended in Dec. 2025 was €-0.04. Its EPS without NRIearnings per share without non-recurring items for the trailing twelve months (TTM) ended in Dec. 2025 was -0.10.

During the past 3 years, the average EPS without NRI Growth Rate was 84.00% per year. During the past 5 years, the average EPS without NRI Growth Rate was 54.10% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EPS without NRI Growth Rate using EPS without NRI data.

During the past 7 years, Prostatype Genomics AB's highest 3-Year average EPS without NRI Growth Rate was 84.00% per year. The lowest was -80.80% per year. And the median was 2.95% per year.

Prostatype Genomics AB  (FRA:PGO0) EPS (Basic) Explanation

EPS is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists EPS without NRI, which better reflects the company's underlying performance.

Be Aware

Compared with Earnings per share, a company's cash flow is better indicator of the company's earnings power.

If a company's earnings per share is less than cash flow per share over long term, investors need to be cautious and find out why.

Prostatype Genomics AB EPS (Basic) Related Terms

Prostatype Genomics AB EPS (Basic) Historical Data

* Premium members only.

The historical data trend for Prostatype Genomics AB's EPS (Basic) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Prostatype Genomics AB EPS (Basic) Chart

Prostatype Genomics AB Annual Data
Trend Jun18 Jun19 Dec21 Dec22 Dec23 Dec24 Dec25
EPS (Basic)
Get a 7-Day Free Trial -5.51 -29.40 -16.80 -0.29 -0.12

Prostatype Genomics AB Semi-Annual Data
Jun18 Jun19 Jun20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
EPS (Basic) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -3,976.37 -1.76 -0.44 -0.06 -0.04
FRA:PGO0
25GF Score
Prostatype Genomics AB FRA:PGO0
EPS (Basic) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Prostatype Genomics AB EPS (Basic) Calculation

EPS (Basic) is a rough measurement of the amount of a company's profit that can be allocated to one share of its stock. Basic earnings per share (EPS) do not factor in the dilutive effects on convertible securities.

Prostatype Genomics AB's Basic EPS for the fiscal year that ended in Dec. 2025 is calculated as

Basic EPS (A: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-4.089-0)/33.784
=-0.12

Prostatype Genomics AB's Basic EPS for the quarter that ended in Dec. 2025 is calculated as

Basic EPS (Q: Dec. 2025 )=(Net Income-Preferred Dividends)/Shares Outstanding (Basic Average)
=(-1.891-0)/51.793
=-0.04

EPS (Basic) for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €-0.10

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EPS (Basic) →
What does a EPS (Basic) of €-0.10 mean?
Prostatype Genomics AB (FRA:PGO0) has a EPS (Basic) of €-0.10 as of Dec. 2025. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Prostatype Genomics AB and its competitors.
Is Prostatype Genomics AB's EPS (Basic) too high?
Prostatype Genomics AB's current EPS (Basic) is €-0.10. Overall, Prostatype Genomics AB has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does Prostatype Genomics AB's EPS (Basic) compare to TMO and DHR?
Prostatype Genomics AB's EPS (Basic) of €-0.10 can be compared against companies in the Medical Diagnostics & Research industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EPS (Basic) for a Medical Diagnostics & Research company?
A good EPS (Basic) depends on the Medical Diagnostics & Research industry context. However, EPS (Basic) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EPS (Basic) mean?
A high EPS (Basic) can signal that a stock is expensive relative to its fundamentals. Earnings per share (basic) equals net income divided by the standard, non-diluted average shares outstanding. View historical data on Prostatype Genomics AB and its competitors. Prostatype Genomics AB's current EPS (Basic) is €-0.10. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Prostatype Genomics AB stock overvalued right now?
Prostatype Genomics AB (FRA:PGO0) has a current EPS (Basic) of €-0.10. The stock's GF Value™ is €0.01, compared to a current price of €0.03 — trading 214% above its estimated fair value. The current EPS (Basic) is €-0.10. Prostatype Genomics AB's overall GF Score™ is 25/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EPS (Basic) calculated?
EPS (Basic) is calculated from a company's financial statements. For Prostatype Genomics AB (FRA:PGO0), the current EPS (Basic) is €-0.10 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Prostatype Genomics AB (FRA:PGO0) Overvalued in 2026?

Based on GuruFocus' analysis, Prostatype Genomics AB stock appears to be overvalued. The current stock price of €0.03 is trading 214% above its estimated GF Value™ of €0.01.

Key valuation signals for FRA:PGO0:

  • EPS (Basic): €-0.10
  • GF Value™: €0.01 vs. price of €0.03 (214% above fair value)
  • GF Score™: 25/100 with 5 warning signs

No single metric tells the full story. See the FRA:PGO0 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Prostatype Genomics AB Business Description

Other Exchanges PROGEN:Sweden
Address Augustendalsvagen 20, Nacka Strand, SWE, 131 52
Prostatype Genomics AB manufactures, markets and sells the prognostic gene test Prostatype. By assessing the aggressiveness of prostate cancer, Prostatype helps clinicians and patients to make correct treatment decisions. Over and under treatment of prostate cancer can be minimized, the quality of life for the patient improved and money can be saved for the health care sector.
25GF Score

Get the complete analysis for FRA:PGO0

EPS (Basic) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.03
Price
€0.01
GF Value